231 related articles for article (PubMed ID: 36870047)
21. Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System.
Wang Z; Lou Y; Wang Q; Sun M; Li X; Wang Y; Wang Y
Clin Drug Investig; 2023 Apr; 43(4):265-275. PubMed ID: 36976423
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.
Reifsnider OS; Tafazzoli A; Linden S; Ishak J; Rakonczai P; Stargardter M; Kuti E
J Am Heart Assoc; 2024 Feb; 13(4):e029042. PubMed ID: 38362909
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.
Davis JA; Booth D; McEwan P; Solomon SD; McMurray JJV; de Boer RA; Comin-Colet J; Bachus E; Chen J
Eur J Heart Fail; 2024 Mar; 26(3):664-673. PubMed ID: 38509642
[TBL] [Abstract][Full Text] [Related]
24. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
Kotit S
Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
[TBL] [Abstract][Full Text] [Related]
25. Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction.
Tang Y; Sang H
ESC Heart Fail; 2023 Aug; 10(4):2524-2533. PubMed ID: 37290665
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.
Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Reifsnider OS; Rakonczai P; Stargardter M; Murata T; Hirase T; Nitta D
J Cardiol; 2023 Jun; 81(6):522-530. PubMed ID: 36858174
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
Liao CT; Yang CT; Toh HS; Chang WT; Chang HY; Kuo FH; Lee MC; Hua YM; Tang HJ; Strong C; Ou HT
Cardiovasc Diabetol; 2021 Oct; 20(1):204. PubMed ID: 34627231
[TBL] [Abstract][Full Text] [Related]
28. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China.
Jiang Y; Zheng R; Sang H
Front Pharmacol; 2021; 12():733681. PubMed ID: 34858172
[No Abstract] [Full Text] [Related]
30. Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China.
Lou Y; Hu T; Huang J
Am J Cardiovasc Drugs; 2023 Jan; 23(1):47-57. PubMed ID: 36207658
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
[TBL] [Abstract][Full Text] [Related]
32. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
Jhund PS
Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
[TBL] [Abstract][Full Text] [Related]
34. Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea.
Kim ES; Park SK; Youn JC; Lee HS; Lee HY; Cho HJ; Choi JO; Jeon ES; Lee SE; Kim MS; Kim JJ; Hwang KK; Cho MC; Chae SC; Kang SM; Park JJ; Choi DJ; Yoo BS; Cho JY; Kim KH; Oh BH; Greenberg B; Baek SH
J Korean Med Sci; 2024 Jan; 39(1):e8. PubMed ID: 38193327
[TBL] [Abstract][Full Text] [Related]
35. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
[TBL] [Abstract][Full Text] [Related]
36. Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE
Fauchier L; Lamblin N; Tardu J; Bellier L; Groyer H; Ittah D; Chollet J; Linden S; Levy P
Pharmacoecon Open; 2024 Jan; 8(1):19-30. PubMed ID: 37606866
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
Liang L; Bin-Chia Wu D; Aziz MIA; Wong R; Sim D; Leong KTG; Wei YQ; Tan D; Ng K
J Med Econ; 2018 Feb; 21(2):174-181. PubMed ID: 28959905
[TBL] [Abstract][Full Text] [Related]
38. Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US.
Talha KM; Butler J; Greene SJ; Aggarwal R; Anker SD; Claggett BL; Solomon SD; McMurray JJV; Vaduganathan M; Fonarow GC
JAMA Cardiol; 2023 Jan; 8(1):66-73. PubMed ID: 36334258
[TBL] [Abstract][Full Text] [Related]
39. The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial.
Booth D; Davis JA; McEwan P; Solomon SD; McMurray JJV; De Boer RA; Comin-Colet J; Bachus E; Chen J
Eur J Heart Fail; 2023 Aug; 25(8):1386-1395. PubMed ID: 37344985
[TBL] [Abstract][Full Text] [Related]
40. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
